FDA — authorised 20 November 2015
- Application: NDA208462
- Marketing authorisation holder: TAKEDA PHARMS USA
- Local brand name: NINLARO
- Indication: CAPSULE — ORAL
- Status: approved
🇺🇸 Ixazomib plus low-dose lenalidomide in United States
FDA authorised Ixazomib plus low-dose lenalidomide on 20 November 2015
Marketing authorisations
FDA
- Status: approved
Ixazomib plus low-dose lenalidomide in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Ixazomib plus low-dose lenalidomide approved in United States?
Yes. FDA authorised it on 20 November 2015; FDA has authorised it.
Who is the marketing authorisation holder for Ixazomib plus low-dose lenalidomide in United States?
TAKEDA PHARMS USA holds the US marketing authorisation.